In a recent meta-analysis, cTns were identified as a predictive marker for the development of cancer therapy-related LV dysfunction in patients receiving various regimens of cytotoxic chemotherapy and/or ERBB2 inhibitor therapy. The gene discussed is ERBB2; the disease is cancer.